Transforming growth factor β1 signal is crucial for dedifferentiation of cancer cells to cancer stem cells in osteosarcoma

Stem Cells

Volumn 31, Issue 3, 2013, Pages 433-446

  Zhang, Haixia ^a   Wu, Haotong ^a   Zheng, Junheng ^a   Yu, Pei ^a   Xu, Lixiao ^a   Jiang, Pan ^a   Gao, Jin ^b   Wang, Hua ^a   Zhang, Yan ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b JAMES COOK UNIVERSITY   (Australia)

Author keywords

Cancer stem cell; Dedifferentiation; Hypoxia; Osteosarcoma; TGF b1; Vascular endothelial cells

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENICITY; CELL DEDIFFERENTIATION; CELL POPULATION; CLONOGENESIS; HUMAN; HUMAN CELL; HYPOXIA; METASTASIS; OSTEOSARCOMA;

ANIMALS; BONE NEOPLASMS; CARCINOGENICITY TESTS; CELL DIFFERENTIATION; CELL LINE, TUMOR; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASTIC STEM CELLS; OSTEOSARCOMA; SIGNAL TRANSDUCTION; SPHEROIDS, CELLULAR; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84874898878     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.1298     Document Type: Article

References (53)

1. Bacci G, Briccoli A, Ferrari S et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity: Long-term results of the Rizzoli's 4th protocol. Eur J Cancer 2001;37: 2030-2039.
2. Mirabello L, Troisi RJ, Savage SA. International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer 2009;125: 229-234.
3. Mohseny AB, Szuhai K, Romeo S et al. Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. J Pathol 2009;219: 294-305.
4. Robey PG, Young MF, Flanders KC et al. Osteoblasts synthesize and respond to transforming growth factor-type beta (TGF-beta) in vitro. J Cell Biol 1987;105: 457-463.
5. Rankin EB, Giaccia AJ, Schipani E. A central role for hypoxic signaling in cartilage, bone, and hematopoiesis. Curr Osteoporos Rep 2011; 9: 46-52.
6. Mundy GR. Malignancy and the skeleton. Horm Metab Res 1997;29: 120-127.
7. Massague J. TGF-beta in cancer. Cell 2008;134: 215-230.
8. Lamouille S, Derynck R. Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. J Cell Biol 2007;178: 437-451.
9. Parvani JG, Taylor MA, Schiemann WP. Noncanonical TGF-beta signaling during mammary tumorigenesis. J Mammary Gland Biol Neoplasia 2011;16: 127-146.
10. Taylor MA, Parvani JG, Schiemann WP. The pathophysiology of epithelial-mesenchymal transition induced by transforming growth factor-beta in normal and malignant mammary epithelial cells. J Mammary Gland Biol Neoplasia 2010;15: 169-190.
11. Tian M, Schiemann WP. The TGF-beta paradox in human cancer: An update. Future Oncol 2009;5: 259-271.
12. Mani SA, Guo W, Liao MJ et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133: 704-715.
13. Gordan JD, Simon MC. Hypoxia-inducible factors: Central regulators of the tumor phenotype. Curr Opin Genet Dev 2007;17: 71-77.
14. Mazumdar J, Dondeti V, Simon MC. Hypoxia-inducible factors in stem cells and cancer. J Cell Mol Med 2009;13: 4319-4328.
15. Bush RS, Jenkin RD, Allt WE et al. Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br J Cancer Suppl 1978;3: 302-306.
16. Teicher BA, Lazo JS, Sartorelli AC. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res 1981;41: 73-81.
17. Mohyeldin A, Garzón-Muvdi T, Quiñones-Hinojosa A. Oxygen in stem cell biology: A critical component of the stem cell niche. Cell Stem Cell 2010;7: 150-161.
18. Kawasoe Y, Yokouchi M, Ueno Y et al. Hyperbaric oxygen as a chemotherapy adjuvant in the treatment of osteosarcoma. Oncol Rep 2009;22: 1045-1050.
19. Clarke MF, Dick JE, Dirks PB et al. Cancer stem cells - Perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006;66: 9339-9344.
20. Charafe-Jauffret E, Ginestier C, Iovino F et al. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res 2010;16: 45-55.
21. Li F, Tiede B, Massague J. Beyond tumorigenesis: Cancer stem cells in metastasis. Cell Res 2007;17: 3-14.
22. Wicha MS. Cancer stem cells and metastasis: Lethal seeds. Clin Cancer Res 2006;12: 5606-5607.
23. Debeb BG, Xu W, Woodward WA. Radiation resistance of breast cancer stem cells: Understanding the clinical framework. J Mammary Gland Biol Neoplasia 2009;14: 11-17.
24. Diehn M, Cho RW, Lobo NA et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009; 458: 780-783.
25. Li X, Lewis MT, Huang J et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008;100: 672-679.
26. Tirino V, Desiderio V, Paino F et al. Human primary bone sarcomas contain CD133+ cancer stem cells displaying high tumorigenicity in vivo. FASEB J 2011;25: 2022-2030.
27. Tang QL, Liang Y, Xie XB et al. Enrichment of osteosarcoma stem cells by chemotherapy. Chin J Cancer 2011;30: 426-432.
28. Adhikari AS, Agarwal N, Wood BM et al. CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance. Cancer Res 2010;70: 4602-4612.
29. Brusevold IJ, Husvik C, Schreurs O et al. Induction of invasion in an organotypic oral cancer model by CoCl2, a hypoxia mimetic. Eur J Oral Sci 2010;118: 168-176.
30. Franchi A, Arganini L, Baroni G et al. Expression of transforming growth factor beta isoforms in osteosarcoma variants: Association of TGF beta 1 with high-grade osteosarcomas. J Pathol 1998;185: 284-289.
31. Yang RS, Wu CT, Lin KH et al. Relation between histological intensity of transforming growth factor-beta isoforms in human osteosarcoma and the rate of lung metastasis. Tohoku J Exp Med 1998;184: 133-142.
32. Xie L, Law BK, Chytil AM et al. Activation of the Erk pathway is required for TGF-beta1-induced EMT in vitro. Neoplasia 2004;6: 603-610.
33. Bhowmick NA, Zent R, Ghiassi M et al. Integrin beta 1 signaling is necessary for transforming growth factor-beta activation of p38MAPK and epithelial plasticity. J Biol Chem 2001;276: 46707-46713.
34. Fuxe J, Vincent T, Garcia HA. Transcriptional crosstalk between TGF-beta and stem cell pathways in tumor cell invasion: Role of EMT promoting Smad complexes. Cell Cycle 2010;9: 2363-2374.
35. Ling L, Nurcombe V, Cool SM. Wnt signaling controls the fate of mesenchymal stem cells. Gene 2009;433: 1-7.
36. Liu F, Kohlmeier S, Wang CY. Wnt signaling and skeletal development. Cell Signal 2008;20: 999-1009.
37. Srivastava S, Ramdass B, Nagarajan S et al. Notch1 regulates the functional contribution of RhoC to cervical carcinoma progression. Br J Cancer 2010;102: 196-205.
38. Sleeman JP, Thiery JP. SnapShot: The epithelial-mesenchymal transition. Cell 2011;145: 162.e1.
39. Chen J, Imanaka N, Chen J et al. Hypoxia potentiates Notch signaling in breast cancer leading to decreased E-cadherin expression and increased cell migration and invasion. Br J Cancer 2010;102: 351-360.
40. Walsh LA, Damjanovski S. IGF-1 increases invasive potential of MCF 7 breast cancer cells and induces activation of latent TGF-beta1 resulting in epithelial to mesenchymal transition. Cell Commun Signal 2011;9: 10-21.
41. Morali OG, Delmas V, Moore R et al. IGF-II induces rapid beta-catenin relocation to the nucleus during epithelium to mesenchyme transition. Oncogene 2001;20: 4942-4950.
42. Allan GJ, Beattie J, Flint DJ. Epithelial injury induces an innate repair mechanism linked to cellular senescence and fibrosis involving IGFbinding protein-5. J Endocrinol 2008;199: 155-164.
43. Eliasson P, Jonsson JI. The hematopoietic stem cell niche: Low in oxygen but a nice place to be. J Cell Physiol 2010;222: 17-22.
44. Lam BS, Adams GB. Blocking HIF1a activity eliminates hematological cancer stem cells. Cell Stem Cell 2011;8: 354-356.
45. Mendez O, Zavadil J, Esencay M et al. Knock down of HIF-1alpha in glioma cells reduces migration in vitro and invasion in vivo and impairs their ability to form tumor spheres. Mol Cancer 2010;9: 133.
46. Chen WL, Feng HJ, Li HG. Expression and significance of hypoxemia- inducible factor-1a in osteosarcoma of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008;106: 254-257.
47. Z CZ, Luo C, Yang Z et al. Heparanase participates in the growth and invasion of human U-2OS osteosarcoma cells and its close relationship with hypoxia-inducible factor-1a in osteosarcoma. Neoplasma 2010;57: 562-571.
48. Yang QC, Zeng BF, Dong Y et al. Overexpression of hypoxia-inducible factor-1a in human osteosarcoma: Correlation with clinicopathological parameters and survival outcome. Jpn J Clin Oncol 2007;37: 127-134.
49. Mizobuchi H, García-Castellano JM, Philip S et al. Hypoxia markers in human osteosarcoma. An exploratory study. Clin Orthop Relat Res 2008;466: 2052-2059.
50. Hess AR, Margaryan NV, Seftor EA et al. Deciphering the signaling events that promote melanoma tumor cell vasculogenic mimicry and their link to embryonic vasculogenesis: Role of the Eph receptors. Dev Dyn 2007;236: 3283-3296.
51. Wang R, Chadalavada K, Wilshire J et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010;4689: 829-833.
52. Chen Y, Jing Z, Luo C et al. Vasculogenic mimicry-potential target for glioblastoma therapy: An in vitro and in vivo study. Med Oncol 2012;29: 324-331
53. Iizuka M, Yamauchi M, Ando K et al. Quantitative RT-PCR assay detecting the transcriptional induction of vascular endothelial growth factor under hypoxia. Biochem Biopys Res Commun 1994;205: 21474-21480.